OrsoBio is developing novel approaches to treat patients with severe metabolic disorders including diabetes, severe dyslipidemias, lipodystrophies, and more.
OrsoBio’s therapies target central pathways of energy metabolism, and our team of physicians and scientists draw on decades of drug development experience.
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
Liver X Receptor (LXR) inhibition to improve plasma triglycerides and cholesterol in patients with severe dyslipidemias
Mitochondrial protonophores to increase energy expenditure and improve metabolic and cardiovascular health in patients with lipodystrophies and other metabolic disorders
ACMSD inhibition to augment NAD+ biosynthesis and improve mitochondrial function in patients with liver and/or kidney dysfunction
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
Liver X Receptor (LXR) inhibition to improve plasma triglycerides and cholesterol in patients with severe dyslipidemias
Mitochondrial protonophores to increase energy expenditure and improve metabolic and cardiovascular health in patients with lipodystrophies and other metabolic disorders
ACMSD inhibition to augment NAD+ biosynthesis and improve mitochondrial function in patients with liver and/or kidney dysfunction
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
Liver X Receptor (LXR) inhibition to improve plasma triglycerides and cholesterol in patients with severe dyslipidemias
Mitochondrial protonophores to increase energy expenditure and improve metabolic and cardiovascular health in patients with lipodystrophies and other metabolic disorders
ACMSD inhibition to augment NAD+ biosynthesis and improve mitochondrial function in patients with liver and/or kidney dysfunction
ACC2 inhibitor | TLC-3593
Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes
LXR inverse agonist | TLC-2716
Liver X Receptor (LXR) inhibition to improve plasma triglycerides and cholesterol in patients with severe dyslipidemias
Mitochondrial protonophore | TLC-6740
Mitochondrial protonophore | TLC-1235
Mitochondrial protonophores to increase energy expenditure and improve metabolic and cardiovascular health in patients with lipodystrophies and other metabolic disorders
ACMSD inhibitor
ACMSD inhibition to augment NAD+ biosynthesis and improve mitochondrial function in patients with liver and/or kidney dysfunction
Focusing on severe metabolic disorders with major morbidity and mortality
Targeting fundamental aspects of metabolism with first-in-class therapies to restore energy homeostasis and prevent organ dysfunction
Dedicated MDs and PhDs with decades of clinical and drug development experience
The OrsoBio team is a group of forward-thinking scientists and proven biotech leaders who are deeply committed to advancing new therapies to help patients with severe metabolic disorders. Our mission is to redefine the treatment of these disorders by addressing their root cause.
The OrsoBio team is a group of forward-thinking scientists and proven biotech leaders who are deeply committed to advancing new therapies to help patients with severe metabolic disorders. Our mission is to redefine the treatment of these disorders by addressing their root cause.
The name OrsoBio is inspired by the remarkable metabolic adaptability of bears (“orso” in Italian) that enables them to avoid serious sequelae despite extreme environmental challenges before and during hibernation, including absence of food, cold temperatures, and immobilization. In this context, OrsoBio is dedicated to developing therapies that restore energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant to maintaining energy balance in the healthy bear.
OrsoBio is developing novel therapies to treat patients with severe metabolic disorders, including diabetes, severe dyslipidemias, lipodystrophies, and more.
connect@orsobio.com
© 2023 OrsoBio, Inc. | Privacy Policy
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.
